ImaginAb and BZL Biologics Extend Licensing Relationship for Imaging Prostate-Specific Membrane Antigen (PSMA) - Agree to collaborate on companion diagnostic imaging agents for BZL’s therapeutic partnerships
June 11, 2012
Inglewood, CA and New York, NY: 11th of June, 2012 — ImaginAb, Inc. and BZL Biologics, LLC have expanded their commercial relationship to include support for “companion” imaging agent applications. Under an amendment to their existing commercial agreement, ImaginAb will provide clinical companion diagnostic capabilities to BZL and BZL-partnered PSMA antibody therapeutic programs, including anti-PSMA tumor-targeted radiopharmaceuticals and antibody drug conjugates (ADCs). This augments the current business relationship that has enabled ImaginAb to re-engineer BZL’s huJ591 anti-PSMA antibody for fast kinetics, optimized for clinical imaging of prostate cancer with Positron Emission Tomography (PET). “We are pleased to be expanding our relationship with BZL in order to utilize imaging to further enhance the utility of BZL’s multiple therapeutic programs, particularly as we obtain clinical data for our PSMA fragment imaging program,” said Dr. Christian Behrenbruch, CEO of ImaginAb.
“Expanding our partnership enables BZL to offer ImaginAb’s advanced PSMA imaging agents to our partnership programs based on our PSMA antibody pipeline,” commented Barry Silverstein, President of BZL Biologics. “This companion diagnostic strategy will enable optimal patient selection, maximization of therapeutic benefit and significantly improved cost-effectiveness.”
About BZL Biologics
BZL Biologics LLC is a privately held biotechnology company based in New York. Its lead program is based on antibody (Ab) targeting of PSMA, a unique cancer-related antigen that is present at high levels in all prostate cancers as well as the neo-vasculature of all types of solid tumors. This provides an exceptional platform on which to build very potent and exquisitely specific anti-tumor agents.
Founded in 2007, ImaginAb, Inc. is a growth-stage biotechnology company specializing in the development of engineered antibody fragments for clinical diagnostic imaging. The company has a significant pipeline of clinical imaging agents under development oriented towards unmet needs in cancer and immunology.
Media and Communications